Clinical Report: Overcoming Resistance Challenges in CAR-T and BsAbs

Overview

This review evaluates advancements in CAR-T cell therapy and bispecific antibodies (BsAbs) in precision immuno-oncology. It discusses innovative molecular designs aimed at overcoming resistance in solid tumors and the importance of combination strategies.

Background

The shift from traditional chemotherapy to precision immunotherapy represents a significant advancement in oncology, particularly for patients with previously untreatable malignancies. Despite the success of immune checkpoint inhibitors, challenges such as primary resistance and adverse events remain prevalent. Understanding the integration of CAR-T cell therapy and BsAbs into treatment regimens is crucial.

Data Highlights

No numerical data provided in the source material.

Key Findings

• CAR-T cell therapy and BsAbs have shown efficacy in hematological cancers.
• Transitioning these therapies to earlier treatment lines may prevent immune exhaustion.
• Innovative molecular engineering of CAR-T and BsAb constructs aims to counteract the immunosuppressive tumor microenvironment.
• Combination strategies with hematopoietic stem cell transplantation and targeted agents are essential for addressing minimal residual disease.
• Clinical data on overall survival and progression-free survival are important for developing therapy frameworks.

Clinical Implications

The timing of CAR-T and BsAb therapies is a critical consideration in treatment regimens. Innovative molecular designs and combination strategies are important for addressing challenges in solid tumors.

Conclusion

This review highlights the importance of optimizing CAR-T and BsAb therapies through strategic sequencing and molecular innovation.

Related Resources & Content

1. Frontiers in Immunology, 2026 -- Resistance mechanisms and overcoming strategies for CAR T-cell therapy in B-cell hematologic malignancies
2. Blood Cancer Journal, 2024 -- Comparative Analysis of Bispecific Antibodies and CAR-T Cell Therapies in Treating Large B-Cell Lymphomas
3. Frontiers in Immunology, 2026 -- Advanced strategies to enhance the safety, persistence, and efficacy of CAR-T cells in solid tumors
4. EurekAlert!, 2025 -- EBMT publishes 2025 clinical practice recommendations for haematopoietic cell transplantation and CAR-T therapy
5. New England Journal of Medicine, 2025 -- Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
6. The ASCO Post — Early-Phase Study Explores CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma
7. EBMT publishes 2025 clinical practice recommendations for haematopoietic cell transplantation and CAR-T therapy | EurekAlert!
8. Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy | New England Journal of Medicine
9. FDA approves epcoritamab-bysp for follicular lymphoma indications | FDA
10. Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial - ScienceDirect
11. Easy as ABC: Managing Toxicities of Antibody-Drug Conjugates, Bispecific Antibodies, and CAR T-Cell Therapies | American Society of Clinical Oncology Educational Book
12. Mechanisms of antigen-dependent resistance to chimeric antigen receptor (CAR)-T cell therapies | Cancer Cell International | Springer Nature Link